Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer

BACKGROUND: Metastatic castration‐resistant prostate cancer (mCRPC) patients have a poor prognosis, and curcumin is known to have antineoplastic properties. On the basis of previous phase I and phase II studies, we investigated whether the association of curcumin with docetaxel could improve prognos...

Descripción completa

Detalles Bibliográficos
Autores principales: Passildas‐Jahanmohan, Judith, Eymard, Jean‐Christophe, Pouget, Mélanie, Kwiatkowski, Fabrice, Van Praagh, Isabelle, Savareux, Laurent, Atger, Marc, Durando, Xavier, Abrial, Catherine, Richard, Damien, Ginzac Couvé, Angeline, Thivat, Emilie, Monange, Brigitte, Chollet, Philippe, Mahammedi, Hakim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982628/
https://www.ncbi.nlm.nih.gov/pubmed/33666378
http://dx.doi.org/10.1002/cam4.3806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982628/
https://www.ncbi.nlm.nih.gov/pubmed/33666378
http://dx.doi.org/10.1002/cam4.3806

Ejemplares similares